Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VP-102
VP-102/ TO-208 · 2 trials · 4 indications
To evaluate the efficacy of YCANTH (VP-102/TO-208) relative to Vehicle by assessing the proportion of subjects achieving complete clearance defined by complete resolution of all common warts as assessed visually by a Blinded Assessor of all treatable common warts, at the EOT Visit (Day 84).
| Arm | Type | Description |
|---|---|---|
| VP-102 (US) / TO-208 (Japan) | EXPERIMENTAL | US: Topical solution, which is a light violet to dark purple, slightly viscous liquid. Japan: Topical solution, which is clear to yellow, slightly viscous liquid. 0.7% (each mL contains 7 mg of cantharidin)/ glass ampule within an applicator. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Administered Topical/every 21 (± 4) days. All treatments will take place within a 75-day period. |
| Vehicle (US) / Vehicle (Japan) | PLACEBO_COMPARATOR | US: Topical solution, which is a light violet to dark purple, slightly viscous liquid. Japan: Topical solution, which is clear to yellow, slightly viscous liquid. No active drug/glass ampule within an applicator. Each applicator contains 0.45 mL without active cantharidin. Administered Topical/every 21 (± 4) days. All treatments will take place within a 75-day period. |
| VP-102 | EXPERIMENTAL | Topical solution, which is a light violet to dark purple, slightly viscous liquid. 0.7% (each mL contains 7 mg of cantharidin)/glass ampule within an applicator. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Administered Topical/every 21 (± 4) days. All treatments will take place within a 75-day period. |
| Vehicle | PLACEBO_COMPARATOR | Topical solution, which is a light violet to dark purple, slightly viscous liquid. No active drug/glass ampule within an applicator. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Administered Topical/every 21 (± 4) days. All treatments will take place within a 75-day period. |
| Name | Type | Description |
|---|---|---|
| VP-102 (US) / TO-208 (Japan) | COMBINATION_PRODUCT | A single-use applicator and applied in sufficient quantity to cover the entirety of each treatable common wart, including approximately a 1 to 2 mm margin of surrounding, healthy skin. The contents of no more than 2 applicators may be applied at each treatment visit. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Occlusive tape (occlusive tape with similar properties should be used across all clinical sites) will be applied to warts that have been treated. Once applied, the occlusive tape should be gently rubbed to maximize adherence to the treated area. |
| Vehicle (US) / Vehicle (Japan) | COMBINATION_PRODUCT | Vehicle is contained in a single-use applicator and applied in sufficient quantity to cover the entirety of each treatable common wart, including approximately a 1 to 2 mm margin of surrounding, healthy skin. The contents of no more than 2 applicators may be applied at each treatment visit. The Vehicle applicator contains the same excipient formulation as the VP-102/TO-208 applicator but does not contain the active pharmaceutical ingredient cantharidin. Occlusive tape (occlusive tape with similar properties should be used across all clinical sites) will be applied to warts that have been treated. Once applied, the occlusive tape should be gently rubbed to maximize adherence to the treated area. |
| VP-102 | COMBINATION_PRODUCT | A single-use applicator and applied in sufficient quantity to cover the entirety of each treatable common wart, including approximately a 1 to 2 mm margin of surrounding, healthy skin. The contents of no more than 2 applicators may be applied at each treatment visit. Each applicator contains 0.45 mL of 0.7% w/v cantharidin. Occlusive tape (occlusive tape with similar properties should be used across all clinical sites) will be applied to warts that have been treated. Once applied, the occlusive tape should be gently rubbed to maximize adherence to the treated area. |
| Vehicle | COMBINATION_PRODUCT | Vehicle is contained in a single-use applicator and applied in sufficient quantity to cover the entirety of each treatable common wart, including approximately a 1 to 2 mm margin of surrounding, healthy skin. The contents of no more than 2 applicators may be applied at each treatment visit. The Vehicle applicator contains the same excipient formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin. Occlusive tape (occlusive tape with similar properties should be used across all clinical sites) will be applied to warts that have been treated. Once applied, the occlusive tape should be gently rubbed to maximize adherence to the treated area. |
Inclusion Criteria: Candidates will be included in the study if they: 1. Are male or female patients ≥ 2 years of age. 2. Are immunocompetent. 3. Have a minimum of 1 treatable common wart (verruca vulgaris) of any size and height: 1. Common warts are considered treatable if they are located an...
VP-102 is an investigational small molecule being developed by Verrica Pharmaceuticals Inc. (VRCA) for the treatment of molluscum contagiosum, condylomata acuminata (external genital warts), and common warts. It is currently in clinical development and has not been approved by the FDA.
VP-102 contains cantharidin, a topical agent that is applied directly to skin lesions. It is being studied for its effects on viral skin infections including molluscum contagiosum, external genital warts caused by human papillomavirus, and common warts.
VP-102 is developed by Verrica Pharmaceuticals Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol VRCA. The drug is also known as TO-208 in Japan.
VP-102 has completed Phase 2 trials for molluscum contagiosum and external genital warts. It is currently being evaluated in two Phase 3 trials for common warts, which are actively recruiting participants in the United States and Japan.
VP-102 has completed two Phase 2 trials: NCT03186378 in molluscum contagiosum and NCT03981822 in external genital warts. Two Phase 3 trials, NCT07246590 and NCT07637734, are currently recruiting for common warts, with a combined target enrollment of 600 participants.
Yes, VP-102 is also known as TO-208 in Japan. The drug is referred to as VP-102 in the United States and as VP-102/TO-208 internationally. Both names refer to the same cantharidin-based topical treatment.